

The Thalidomide  
Statement of Financial Activities  
for the Year Ended 31 October 2024

	Notes	Unrestricted fund £	Restricted funds £	31.10.24 Total funds £	31.10.23 Total funds £
<b>INCOME AND ENDOWMENTS FROM</b>					
Donations and legacies		10,002	1,574	11,576	2,691
<b>Charitable activities</b>					
Grant income		-	7,693	7,693	-
Investment income	3	14,935	101	15,036	16,729
Other income		14,614	-	14,614	13,910
<b>Total</b>		<u>39,551</u>	<u>9,368</u>	<u>48,919</u>	<u>33,330</u>
<b>EXPENDITURE ON</b>					
<b>Charitable activities</b>					
Staff costs		16,335	582	16,917	38,288
Other charges		54,266	926	55,192	99,176
<b>Total</b>		<u>70,601</u>	<u>1,508</u>	<u>72,109</u>	<u>137,464</u>
Net gains/(losses) on investments		<u>44,291</u>	<u>-</u>	<u>44,291</u>	<u>(33,956)</u>
<b>NET INCOME/(EXPENDITURE)</b>		13,241	7,860	21,101	(138,090)
<b>Transfers between funds</b>	10	<u>(1,899)</u>	<u>1,899</u>	<u>-</u>	<u>-</u>
<b>Net movement in funds</b>		11,342	9,759	21,101	(138,090)
<b>RECONCILIATION OF FUNDS</b>					
Total funds brought forward		404,611	8,509	413,120	551,210
<b>TOTAL FUNDS CARRIED FORWARD</b>		<u><u>415,953</u></u>	<u><u>18,268</u></u>	<u><u>434,221</u></u>	<u><u>413,120</u></u>

The notes form part of these financial

## The Thalidomide

### Balance Sheet

31 October 2024

	Notes	Unrestricted fund £	Restricted funds £	31.10.24 Total funds £	31.10.23 Total funds £
<b>CURRENT ASSETS</b>					
Debtors	7	14,749	-	14,749	1,183
Investments	8	386,714	-	386,714	373,278
Cash at bank		16,794	18,268	35,062	41,185
		<u>418,257</u>	<u>18,268</u>	<u>436,525</u>	<u>415,646</u>
<b>CREDITORS</b>					
Amounts falling due within one year	9	(2,304)	-	(2,304)	(2,526)
<b>NET CURRENT ASSETS</b>		<u>415,953</u>	<u>18,268</u>	<u>434,221</u>	<u>413,120</u>
<b>TOTAL ASSETS LESS CURRENT LIABILITIES</b>		<u>415,953</u>	<u>18,268</u>	<u>434,221</u>	<u>413,120</u>
<b>NET ASSETS</b>		<u>415,953</u>	<u>18,268</u>	<u>434,221</u>	<u>413,120</u>
<b>FUNDS</b>	10				
Unrestricted funds				415,953	404,611
Restricted funds				18,268	8,509
<b>TOTAL FUNDS</b>				<u>434,221</u>	<u>413,120</u>

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 October 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 October 2024 in accordance with Section 476 of the Companies Act 2006.

The trustees acknowledge their responsibilities for

- ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
- preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.

The notes form part of these financial

The Thalidomide

These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime.

The financial statements were approved by the Board of Trustees and authorised for issue on .....15/03/2025..... and were signed on its behalf by:

The notes form part of these financial

Page

continued.

The Thalidomide

Balance Sheet -  
continued 31 October

Ⓢ *Mansell*  
Mr D Mansell - Trustee

D. Mansell

## 1. GENERAL INFORMATION

The Thalidomide Society is a Charitable Incorporated Organisation (CIO). Its principal activity is to work with thalidomide and similarly impaired people, their families and supporters, providing a social network for thalidomide and similarly impaired people. Its registered office is Flat 29, Weymouth House, Hill House Mews, Bromley, BR2 0DD

### Company Status

The charity is a Charitable Incorporated Organisation (CIO). It is registered on Companies House with the company number CE018092 but is not required to submit accounts or other documents with them. The company is registered with The Charity Commission with the charity number 231708. It is required to file an annual report with them which includes a copy of these accounts.

## 2. ACCOUNTING POLICIES

### Basis of preparing the financial statements

The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

### Income

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

### Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

### Taxation

The charity is exempt from corporation tax on its charitable activities.

### Fund accounting

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

## The Thalidomide

### Notes to the Financial

#### Statements for the Year Ended

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

### **Pension costs and other post-retirement benefits**

The charitable company operates a defined contribution pension scheme. Contributions payable to the charitable company's pension scheme are charged to the Statement of Financial Activities in the period to which they relate.

### **Debtors**

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid.

## 2. ACCOUNTING POLICIES

### - continued Cash at bank and in hand

Cash at bank and in hand includes cash and short-term liquid investments with a short maturity of 3 months or less from the date of acquisition or opening of the deposit or similar account.

## Liabilities

Liabilities are recognised when there is an obligation at the Balance sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably.

Liabilities are recognised at the amount that the charity anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide.

## 3. INVESTMENT INCOME

	31.10.24 £	31.10.23 £
Investment income	15,036	16,729

## 4. TRUSTEES' REMUNERATION AND BENEFITS

There were no trustees' remuneration or other benefits for the year ended 31 October 2024 nor for the year ended 31 October 2023.

## Trustees' expenses

During the year some trustees were paid expenses to cover travel costs. The amount of these payments made were £1,098 (2023 - £1,068).

## 5. STAFF COSTS

	31.10.24 £	31.10.23 £
Wages and salaries	13,602	32,068
Other pension costs	1,089	1,084
	14,691	33,152

The average monthly number of employees during the year was as follows:

<u>The Thalidomide</u>	31.10.24	31.10.23
Employees	1	2
<u>Notes to the Financial Statements -</u>	<u></u>	<u></u>
continued for the Year Ended 31		
No employees received emoluments in excess of £60,000.		



## 6. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES

	Unrestricted fund £	Restricted funds £	Total funds £
<b>INCOME AND ENDOWMENTS FROM</b>			
Donations and legacies	90	2,601	2,691
Investment income	16,681	48	16,729
Other income	13,910	-	13,910
<b>Total</b>	<u>30,681</u>	<u>2,649</u>	<u>33,330</u>
<b>EXPENDITURE ON</b>			
<b>Charitable activities</b>			
Staff costs	29,072	9,216	38,288
Other charges	84,461	14,715	99,176
<b>Total</b>	<u>113,533</u>	<u>23,931</u>	<u>137,464</u>
Net gains/(losses) on investments	<u>(33,956)</u>	<u>-</u>	<u>(33,956)</u>
<b>NET INCOME/(EXPENDITURE)</b>	(116,808)	(21,282)	(138,090)
<b>Transfers between funds</b>	<u>(8,000)</u>	<u>8,000</u>	<u>-</u>
<b>Net movement in funds</b>	(124,808)	(13,282)	(138,090)
<b>RECONCILIATION OF FUNDS</b>			
Total funds brought forward	529,419	21,791	551,210
<b>TOTAL FUNDS CARRIED FORWARD</b>	<u>404,611</u>	<u>8,509</u>	<u>413,120</u>

## 7. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	31.10.24 £	31.10.23 £
PAYE & NI debtor	1,183	1,183
Prepayments and accrued income	<u>13,566</u>	<u>-</u>
	14,749	1,183

The Thalidomide

Notes to the Financial Statements -  
continued for the Year Ended 31

**8. CURRENT ASSET INVESTMENTS**

	31.10.24	31.10.23
	£	£
Listed investments	386,714	373,278

**9. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	31.10.24	31.10.23
	£	£
Pension creditor	109	78
Accruals and deferred income	2,195	2,448
	<u>2,304</u>	<u>2,526</u>

**10. MOVEMENT IN FUNDS**

	At 1.11.23 £	Net movement in funds £	Transfers between funds £	At 31.10.24 £
<b>Unrestricted funds</b>				
General fund	404,611	13,241	(1,899)	415,953
<b>Restricted funds</b>				
Thalidomide Society Oral History	13,506	111	-	13,617
Srey Hang & Beyond	4,595	56	-	4,651
HLF	(9,592)	7,693	1,899	-
	<u>8,509</u>	<u>7,860</u>	<u>1,899</u>	<u>18,268</u>
<b>TOTAL FUNDS</b>	<u>413,120</u>	<u>21,101</u>	<u>-</u>	<u>434,221</u>

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Gains and losses £	Movement in funds £
<b>Unrestricted funds</b>				
General fund	39,551	(70,601)	44,291	13,241
<b>Restricted funds</b>				
Thalidomide Society Oral History	1,619	(1,508)	-	111
Srey Hang & Beyond	56	-	-	56
HLF	7,693	-	-	7,693
	<u>9,368</u>	<u>(1,508)</u>	<u>-</u>	<u>7,860</u>
<b>TOTAL FUNDS</b>	<u>48,919</u>	<u>(72,109)</u>	<u>44,291</u>	<u>21,101</u>

## The Thalidomide

### Notes to the Financial Statements - continued for the Year Ended 31

#### 10. MOVEMENT IN FUNDS - continued

##### Comparatives for movement in funds

	At 1.11.22 £	Net movement in funds £	Transfers between funds £	At 31.10.23 £
<b>Unrestricted funds</b>				
General fund	529,419	(116,808)	(8,000)	404,611
<b>Restricted funds</b>				
Thalidomide Society Oral History	10,898	2,608	-	13,506
Support for Srey Hang	4,556	39	-	4,595
HLF	6,337	(23,929)	8,000	(9,592)
	<u>21,791</u>	<u>(21,282)</u>	<u>8,000</u>	<u>8,509</u>
<b>TOTAL FUNDS</b>	<u><u>551,210</u></u>	<u><u>(138,090)</u></u>	<u><u>-</u></u>	<u><u>413,120</u></u>

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Gains and losses £	Movement in funds £
<b>Unrestricted funds</b>				
General fund	30,681	(113,533)	(33,956)	(116,808)
<b>Restricted funds</b>				
Thalidomide Society Oral History	2,608	-	-	2,608
Support for Srey Hang	39	-	-	39
HLF	2	(23,931)	-	(23,929)
	<u>2,649</u>	<u>(23,931)</u>	<u>-</u>	<u>(21,282)</u>
<b>TOTAL FUNDS</b>	<u><u>33,330</u></u>	<u><u>(137,464)</u></u>	<u><u>(33,956)</u></u>	<u><u>(138,090)</u></u>

#### 11. RELATED PARTY DISCLOSURES

There were no related party transactions for the year ended 31 October 2024.

## The Thalidomide

### Detailed Statement of Financial Activities for the Year Ended 31

	31.10.24 £	31.10.23 £
<b>INCOME AND ENDOWMENTS</b>		
<b>Donations and legacies</b>		
Donations	10,003	1,191
Lottery income	1,573	1,500
	<hr/> 11,576	<hr/> 2,691
<b>Investment income</b>		
Investment income	15,036	16,729
<b>Charitable activities</b>		
Grants	7,693	-
<b>Other income</b>		
Delgate fees	14,614	13,910
	<hr/> 48,919	<hr/> 33,330
<b>Total incoming resources</b>		
<b>EXPENDITURE</b>		
<b>Support costs</b>		
<b>Human resources</b>		
Wages	13,602	32,068
Pensions	1,089	1,084
Travel and subsistence costs	2,226	5,136
	<hr/> 16,917	<hr/> 38,288
<b>Other</b>		
Insurance	96	254
Telephone and communications	445	726
Postage and stationery	609	260
Computer and IT expenses	977	1,677
Training seminars & workshops	44,278	78,207
Oral history photography costs	-	7,946
Oral history transcribing costs	-	4,243
Memberships and subscriptions	95	-
Repairs and renewals	-	1,198
Recruitment costs	-	633
Gifts	71	-
Website development	4,560	-
Investment fees	856	1,137
Carried forward	51,987	96,281

This page does not form part of the statutory financial

The Thalidomide

Detailed Statement of Financial

Activities for the Year Ended 31

	31.10.24	31.10.23
	£	£
<b>Other</b>		
Brought forward	51,987	96,281
Accountancy fees	2,130	2,034
Legal fees	1,075	861
	<hr/>	<hr/>
	55,192	99,176
	<hr/>	<hr/>
Total resources expended	72,109	137,464
	<hr/>	<hr/>
<b>Net expenditure before gains and losses</b>	(23,190)	(104,134)
	<hr/>	<hr/>
<b>Realised recognised gains and losses</b>		
Realised gains/(losses) on fixed asset investments	44,291	(33,956)
	<hr/>	<hr/>
<b>Net income/(expenditure)</b>	21,101	(138,090)
	<hr/> <hr/>	<hr/> <hr/>

This page does not form part of the statutory financial